Display options
Cite
Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015;8:519-28doi: 10.2147/OTT.S30793.
Benafif, S., & Hall, M. (2015). An update on PARP inhibitors for the treatment of cancer. OncoTargets and therapy, 8519-28. https://doi.org/10.2147/OTT.S30793
Benafif, Sarah, and Hall, Marcia. "An update on PARP inhibitors for the treatment of cancer." OncoTargets and therapy vol. 8 (2015): 519-28. doi: https://doi.org/10.2147/OTT.S30793
Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015. PMID: 25750544; PMCID: PMC4348139.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.

An update on PARP inhibitors for the treatment of cancer.

OncoTargets and therapy

Sarah Benafif, Marcia Hall

Affiliations

  1. Mount Vernon Cancer Centre, Northwood, Middlesex, UK.

PMID: 25750544 PMCID: PMC4348139 DOI: 10.2147/OTT.S30793

Abstract

The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers. This article attempts to summarize the rationale and theory behind PARPi, the clinical trials already reported, as well as ongoing studies designed to determine the role of PARPi in patients with and without germline mutations of BRCA genes. Future plans for PARPi both as monotherapy and in combination with standard cytotoxics, other biological agents, and as radiosensitizers are also covered. The widening scope of PARPi adds another important targeted agent to the growing list of molecular inhibitors; future and ongoing trials will identify the most effective role for PARPi, including for patients other than BRCA germline mutation carriers.

Keywords: BRCA genes; BRCA germline mutation carriers; PARPi; cytotoxics; germline mutations; radiosensitizers

References

  1. Cancer Res. 2012 Nov 1;72 (21):5588-99 - PubMed
  2. Mol Aspects Med. 2013 Dec;34(6):1217-56 - PubMed
  3. J Clin Oncol. 2007 Nov 20;25(33):5165-71 - PubMed
  4. Semin Oncol. 1996 Apr;23(2):251-75 - PubMed
  5. EMBO Mol Med. 2009 Sep;1(6-7):315-22 - PubMed
  6. Cancer Res. 2002 Jul 1;62(13):3789-93 - PubMed
  7. Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103 - PubMed
  8. J Natl Cancer Inst. 2000 Jun 7;92 (11):924-30 - PubMed
  9. Trends Biochem Sci. 2010 Apr;35(4):208-19 - PubMed
  10. J Clin Oncol. 2005 Jul 20;23(21):4626-33 - PubMed
  11. J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 - PubMed
  12. J Cancer Res Clin Oncol. 1996;122(11):665-70 - PubMed
  13. Cancer Res. 2006 Aug 15;66(16):8109-15 - PubMed
  14. Lancet Oncol. 2013 Aug;14(9):882-92 - PubMed
  15. Surg Oncol Clin N Am. 1998 Jan;7(1):1-23 - PubMed
  16. Breast Cancer Res. 2013;15(5):R88 - PubMed
  17. Clin Cancer Res. 2008 Jun 15;14(12):3916-25 - PubMed
  18. J Clin Oncol. 2009 Nov 20;27(33):5601-6 - PubMed
  19. J Clin Oncol. 2010 Jan 20;28(3):375-9 - PubMed
  20. J Clin Oncol. 2011 Sep 20;29(27):3659-68 - PubMed
  21. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
  22. Cancer Discov. 2012 Nov;2(11):1036-47 - PubMed
  23. N Engl J Med. 2009 Jul 9;361(2):123-34 - PubMed
  24. Lancet. 2010 Jul 24;376(9737):235-44 - PubMed
  25. J Gastroenterol Hepatol. 2001 Mar;16(3):338-44 - PubMed
  26. PLoS One. 2013;8(4):e60408 - PubMed
  27. Clin Cancer Res. 2007 May 15;13(10):3033-42 - PubMed
  28. Nature. 2011 Jun 29;474(7353):609-15 - PubMed
  29. Cell Cycle. 2011 Apr 15;10(8):1192-9 - PubMed
  30. Cancer Res. 2011 Sep 1;71(17):5626-34 - PubMed
  31. Nat Commun. 2014 Jul 21;5:4426 - PubMed
  32. Nat Rev Clin Oncol. 2011 May;8(5):302-6 - PubMed
  33. Nature. 2008 Feb 28;451(7182):1111-5 - PubMed
  34. Br J Cancer. 2007 Jan 15;96(1):11-5 - PubMed
  35. Cell Cycle. 2009 Jul 15;8(14):2198-210 - PubMed
  36. Lancet Oncol. 2011 Sep;12(9):852-61 - PubMed
  37. Sci Transl Med. 2010 Oct 13;2(53):53ra75 - PubMed
  38. Breast Cancer Res Treat. 2009 May;115(2):359-63 - PubMed
  39. J Natl Cancer Inst. 2004 Jan 7;96(1):56-67 - PubMed
  40. Clin Cancer Res. 2011 Mar 1;17(5):1082-9 - PubMed
  41. Ann Oncol. 2014 Jan;25(1):32-40 - PubMed
  42. Nat Rev Cancer. 2004 Oct;4(10):814-9 - PubMed
  43. J Clin Oncol. 2010 May 20;28(15):2512-9 - PubMed
  44. Clin Cancer Res. 2012 Mar 15;18(6):1726-34 - PubMed
  45. Eur Urol. 2013 May;63(5):920-6 - PubMed
  46. Oncogene. 2014 Jul 24;33(30):3894-907 - PubMed
  47. Eur J Cancer. 2013 Sep;49(14):2972-8 - PubMed
  48. Am J Hum Genet. 2003 Feb;72(2):270-80 - PubMed
  49. Oncologist. 2011;16(10):1397-402 - PubMed
  50. J Med Chem. 2008 Oct 23;51(20):6581-91 - PubMed
  51. Nature. 2005 Apr 14;434(7035):917-21 - PubMed
  52. Eur J Cancer. 2007 Sep;43(14 ):2124-33 - PubMed
  53. Cancer Chemother Pharmacol. 2013 May;71(5):1191-9 - PubMed
  54. Am J Hematol. 1991 Aug;37(4):223-7 - PubMed
  55. N Engl J Med. 2012 Apr 12;366(15):1382-92 - PubMed
  56. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84 - PubMed
  57. Cancer Discov. 2013 Jan;3(1):68-81 - PubMed
  58. Invest New Drugs. 2012 Aug;30(4):1493-500 - PubMed
  59. Front Oncol. 2014 Feb 27;4:19 - PubMed
  60. Onco Targets Ther. 2013 Sep 03;6:1197-206 - PubMed
  61. Mol Cancer Ther. 2011 Jul;10(7):1185-93 - PubMed
  62. Am J Hum Genet. 2003 May;72(5):1117-30 - PubMed

Publication Types